AUA Highlights

There has been increased focus on the study of tumor alterations that may predict treatment benefit or serve as possible actionable targets for new therapeutic approaches in cancer. Read More ›

Circulating tumor DNA (ctDNA) analysis is a useful sequencing platform in metastatic castration-resistant prostate cancer (CRPC), and ctDNA alterations are detected in most patients with this type of prostate cancer, according to Justin Shaya, MD, Hematology/Oncology Fellow, UC San Diego Moores Cancer Center, CA. Read More ›

Preliminary results from a single-arm study demonstrated promising progression-free survival (PFS) and a clinically meaningful objective response rate (ORR) with the combination of pembrolizumab (Keytruda) and nab-paclitaxel (Abraxane) as second- or third-line therapy in patients with advanced urothelial carcinoma. Read More ›

Treatment with a combination of pembrolizumab (Keytruda) and enzalutamide (Xtandi) continues to show substantial activity in patients with metastatic castration-resistant prostate cancer (CRPC) who have already been treated with abiraterone (Zytiga), according to results of a recent clinical trial, which were presented during the virtual 2020 American Urological Association Annual Meeting. Read More ›


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: